Decontamination of prions in a plasma product manufacturing environment

Transfusion

Volumn 54, Issue 4, 2014, Pages 1028-1036

  Bellon, Anne ^a   Comoy, Emmanuel ^b   Simoneau, Steve ^a   Mornac, Sandrine ^a   Dehen, Capucine ^b   Perrin, Audrey ^b   Arzel, Aude ^a   Arrabal, Samuel ^a   Baron, Henry ^c   Laude, Hubert ^d   You, Bruno ^a   Deslys, Jean Philippe ^b   Flan, Benoit ^a  

^a LFB   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c Atlantic Biotech SRO   (Czech Republic)

^d INRA Institut National de la Recherche Agronomique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PRION PROTEIN; RESIN; SODIUM HYDROXIDE; STAINLESS STEEL;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BLOOD; BRAIN HOMOGENATE; CONTROLLED STUDY; ENVIRONMENTAL SANITATION; GEL CHROMATOGRAPHY; IMMUNOCHEMISTRY; INDUSTRIAL AREA; INDUSTRIAL MEDICINE; ION EXCHANGE CHROMATOGRAPHY; MOUSE; NONHUMAN; PRION; VIRAL CONTAMINATION; VIRUS DETECTION; VIRUS INACTIVATION;

ANIMALS; BLOOD BANKS; CRICETINAE; DECONTAMINATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENT, CONTROLLED; EQUIPMENT CONTAMINATION; HUMANS; MANUFACTURED MATERIALS; MESOCRICETUS; MICE; PLASMA; PRIONS; SODIUM HYDROXIDE; STAINLESS STEEL;

EID: 84898901580     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12381     Document Type: Article

References (36)

1. Prusiner SB,. Molecular biology of prion diseases. Science 1991; 252: 1515-1522. (Pubitemid 21917065)
2. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, Will RG,. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-421. (Pubitemid 38210057)
3. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW,. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-529. (Pubitemid 39070413)
4. Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, Joiner S, Linehan JM, Brandner S, Wadsworth JD, Hewitt P, Collinge J,. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006; 368: 2061-2067. (Pubitemid 44855106)
5. Health protection report Volume 1 Number 3 published on the 19th of January 2007 "Current news" Fourth case of transfusion-associated variant-CJD infection [monograph on the internet]. London: Health Protection Agency; 2007. [cited 17 January 2007]: http://www.hpa.org.uk/hpr/archives/2007/ hpr0307.pdf
6. Peden A, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Keeling DM, Millar CM, Hill FG, Ironside JW,. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304.
7. ANSM. Analyse de risque de transmission de la variante de la Maladie de Creutzfeldt-Jakob (vMCJ) par les produits de santé d'origine humaine. 2009.
8. Zaman SM, Hill FG, Palmer B, Millar CM, Bone A, Molesworth AM, Connor N, Lee CA, Dolan G, Wilde JT, Gill ON, Makris M,. The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products. Haemophilia 2011; 17: 931-937.
9. McCutcheon S, Alejo Blanco AR, Houston EF, de Wolf C, Tan BC, Smith A, Groschup MH, Hunter N, Hornsey VS, MacGregor IR, Prowse CV, Turner M, Manson JC,. All clinically-relevant blood components transmit prion disease following a single blood transfusion: a sheep model of vCJD. PloS ONE 2011; 6: e23169.
10. Brown P, Cervenakova L, McShane LM, Barber P, Rubenstein R, Drohan WN,. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-1178.
11. You B, Aubin JT, Le-Hir G, Arzel A, Laude H, Flan B,. In vitro infectivity assay for prion titration for application to the evaluation of the prion removal capacity of biological products manufacturing processes. J Virol Methods 2010; 164: 1-6.
12. Burnouf T, Padilla A,. Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol 2006; 13: 320-328. (Pubitemid 46188558)
13. Flan B, Martin M, Trouvin JH,. Plasma derived products and the challenges in the spiking materials and validation studies. In:, Riesner D, Deslys J, Pocchiari M, Somerville R, editors. Decontamination of prions. Düsseldorf: Düsseldorf University Press; 2012. p. 167-194.
14. Rohwer RG,. Scrapie infectious agent is virus-like in size and susceptibility to inactivation. Nature 1984; 308: 658-662. (Pubitemid 14129581)
15. Baron H, Prusiner S,. Biosafety of prion diseases. In:, Fleming D, Hunt DL, editors. Biological safety-principles and practices. Washington, D.C.: American Society of Microbiology Press; 2006. p. 461-485.
16. Fichet G, Comoy E, Duval C, Antloga K, Dehen C, Charbonnier A, McDonnell G, Brown P, Lasmezas CI, Deslys JP,. Novel methods for disinfection of prion-contaminated medical devices. Lancet 2004; 364: 521-526. (Pubitemid 39070412)
17. Race RE, Raymond GJ,. Inactivation of transmissible spongiform encephalopathy (prion) agents by environ LpH. J Virol 2004; 78: 2164-2165. (Pubitemid 38176750)
18. Barret A, Tagliavini F, Forloni G, Bate C, Salmona M, Colombo L, De Luigi A, Limido L, Suardi S, Rossi G, Auvre F, Adjou KT, Sales N, Williams A, Lasmezas C, Deslys JP,. Evaluation of quinacrine treatment for prion diseases. J Virol 2003; 77: 8462-8469. (Pubitemid 36871474)
19. Finney DJ,. The median lethal dose and its estimation. Arch Toxicol 1985; 56: 215-218. (Pubitemid 15104912)
20. Kaplan E, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG,. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39. (Pubitemid 8018922)
22. Archer F, Bachelin C, Andreoletti O, Besnard N, Perrot G, Langevin C, Le Dur A, Vilette D, Baron-Van Evercooren A, Vilotte JL, Laude H,. Cultured peripheral neuroglial cells are highly permissive to sheep prion infection. J Virol 2004; 78: 482-490. (Pubitemid 37549758)
23. Kasermann F, Kempf C,. Sodium hydroxide renders the prion protein PrPSc sensitive to proteinase K. J Gen Virol 2003; 84: 3173-3176. (Pubitemid 37336802)
24. Unal A, Thyer J, Uren E, Middleton D, Braun M, Maher D,. Investigation by bioassay of the efficacy of sodium hydroxide treatment on the inactivation of mouse-adapted scrapie. Biologicals 2007; 35: 161-164. (Pubitemid 46891846)
25. Bauman PA, Lawrence LA, Biesert L, Dichtelmuller H, Fabbrizzi F, Gajardo R, Groner A, Jorquera JI, Kempf C, Kreil TR, von Hoegen I, Pifat DY, Petteway SR Jr, Cai K,. Critical factors influencing prion inactivation by sodium hydroxide. Vox Sang 2006; 91: 34-40. (Pubitemid 43822302)
26. Taylor DM, Fraser H, McConnell I, Brown DA, Brown KL, Lamza KA, Smith GR,. Decontamination studies with the agents of bovine spongiform encephalopathy and scrapie. Arch Virol 1994; 139: 313-326.
27. Somerville RA, Oberthur RC, Havekost U, MacDonald F, Taylor DM, Dickinson AG,. Characterization of thermodynamic diversity between transmissible spongiform encephalopathy agent strains and its theoretical implications. J Biol Chem 2002; 277: 11084-11089. (Pubitemid 34952868)
28. Giles K, Glidden DV, Beckwith R, Seoanes R, Peretz D, DeArmond SJ, Prusiner SB,. Resistance of bovine spongiform encephalopathy (BSE) prions to inactivation. Plos Pathog 2008; 4: e1000206.
29. Brown P, Rohwer RG, Gajdusek DC,. Newer data on the inactivation of scrapie virus or Creutzfeldt-Jakob disease virus in brain tissue. J Infect Dis 1986; 153: 1145-1148. (Pubitemid 16086784)
30. Di Martino A, Safar J, Ceroni M, Gibbs CJ Jr,. Purification of non-infectious ganglioside preparations from scrapie-infected brain tissue. Arch Virol 1992; 124: 111-121.
31. Cervenakova L, Yakovleva O, McKenzie C, Kolchinsky S, McShane L, Drohan WN, Brown P,. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 2003; 43: 1687-1694. (Pubitemid 37518076)
32. Gregori L, Yang H, Anderson S,. Estimation of variant Creutzfeldt-Jakob disease infectivity titers in human blood. Transfusion 2011; 51: 2596-2602.
33. Zobeley E, Flechsig E, Cozzio A, Enari M, Weissmann C,. Infectivity of scrapie prions bound to a stainless steel surface. Mol Med 1999; 5: 240-243. (Pubitemid 29279752)
34. Flechsig E, Hegyi I, Enari M, Schwarz P, Collinge J, Weissmann C,. Transmission of scrapie by steel-surface-bound prions. Mol Med 2001; 7: 679-684. (Pubitemid 33070982)
35. Thyer J, Unal A, Hartel G, Middleton D, Bingham J, Braun M, Uren E, Maher D,. Investigation of prion removal/inactivation from chromatographic gel. Vox Sang 2006; 91: 301-308. (Pubitemid 44720164)
36. Foster PR, Griffin BD, Bienek C, McIntosh RV, MacGregor IR, Somerville RA, Steele PJ, Reichl HE,. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII. Vox Sang 2004; 86: 92-99. (Pubitemid 38436886)